Should I buy or sell Rocket Pharmaceuticals stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RCKT shares. View RCKT analyst ratings or view top-rated stocks .

What is Rocket Pharmaceuticals' stock price target for 2024?

9 brokerages have issued 12-month target prices for Rocket Pharmaceuticals' shares. Their RCKT share price targets range from $39.00 to $65.00. On average, they predict the company's share price to reach $52.13 in the next twelve months. This suggests a possible upside of 120.1% from the stock's current price. View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts .

How have RCKT shares performed in 2024?

Rocket Pharmaceuticals' stock was trading at $29.97 at the beginning of 2024. Since then, RCKT shares have decreased by 21.0% and is now trading at $23.68. View the best growth stocks for 2024 here .

When is Rocket Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our RCKT earnings forecast .

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its quarterly earnings results on Monday, February, 26th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.14. During the same period in the previous year, the business posted ($0.92) EPS.

What ETFs hold Rocket Pharmaceuticals' stock?

ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) , Harbor Health Care ETF (MEDI) , Harbor Disruptive Innovation ETF (INNO) , Putnam BioRevolution ETF (SYNB) and SPDR S&P Biotech ETF (XBI) . Franklin Genomic Advancements ETF (HELX) .

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX) , Pfizer (PFE) , SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , Amarin (AMRN) , Energy Transfer (ET) , Micron Technology (MU) , VBI Vaccines (VBIV) , Vaxart (VXRT) and Alibaba Group (BABA) .

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.26%) and Harbour Capital Advisors LLC (0.02%). Insiders that own company stock include David P Southwell, Gaurav Shah , Gotham Makker , John Militello , Jonathan David Schwartz , Kinnari Patel, Mark Andrew White, Martin Wilson and Rtw Investments, Lp. View institutional ownership trends .

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RCKT

Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free RCKT Stock Alerts

$23.68

-0.57 (-2.35%)

(As of 04/17/2024 ET)

Compare

Today's Range: $23.49
▼
$24.56
50-Day Range: $23.68
▼
$30.74
52-Week Range: $14.89
▼
$32.53

Volume: 640,566 shs
Average Volume: 717,385 shs
Market Capitalization: $2.14 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $52.13

Get Rocket Pharmaceuticals alerts:

Rocket Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.89 Rating Score
Upside/Downside: 120.1% Upside
$52.13 Price Target
Short Interest: Bearish
11.62% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: 0.28
Based on 15 Articles This Week
Insider Trading: Selling Shares
$11.47 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.94) to ($1.91) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.37 out of 5 stars

Medical Sector

109th out of 914 stocks

Pharmaceutical Preparations Industry

32nd out of 406 stocks

4.4

Analyst's Opinion

Consensus Rating
Rocket Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Rocket Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
11.62% of the outstanding shares of Rocket Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Rocket Pharmaceuticals has recently increased by 2.73%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Rocket Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Rocket Pharmaceuticals does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Rocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Rocket Pharmaceuticals is -0.81.

1.8

News and Social Media Coverage

News Sentiment
Rocket Pharmaceuticals has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 15 news articles for Rocket Pharmaceuticals this week, compared to 9 articles on an average week.
Search Interest
Only 5 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,474,727.00 in company stock.
Percentage Held by Insiders
31.10% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($2.94) to ($1.91) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rocket Pharmaceuticals is -8.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rocket Pharmaceuticals is -8.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rocket Pharmaceuticals has a P/B Ratio of 4.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Rocket Pharmaceuticals Stock (NASDAQ:RCKT)

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

RCKT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RCKT Stock News Headlines

April 12, 2024 | insidertrades.com

Mark Andrew White Sells 12,532 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock

March 26, 2024 | insidertrades.com

John Militello Sells 2,490 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock

April 17, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 26, 2024 | insidertrades.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Director Sells $7,789,820.00 in Stock

April 17, 2024 | msn.com

Injured South Carolina tailback Rocket Sanders has a timetable in mind for return

April 17, 2024 | msn.com

Brevard political consultant, Space Coast Rocket owner, arrested for alleged PPP loan fraud

April 13, 2024 | techcrunch.com

Space Force tees up new ‘responsive space’ mission from Rocket Lab and True Anomaly

April 12, 2024 | msn.com

Beloved Durant Rocket Park slide staying after all

April 17, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 12, 2024 | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Reaffirmed by Needham & Company LLC

April 12, 2024 | msn.com

Rocket League Sideswipe Codes For April 2024

April 11, 2024 | yahoo.com

Space Force tees up new 'responsive space' mission from Rocket Lab and True Anomaly

April 11, 2024 | msn.com

Durant Rocket Park, Multi-Sports Complex to begin renovations

April 10, 2024 | usnews.com

Russia Aborts Angara-A5 Space Rocket Launch for Second Time

April 5, 2024 | msn.com

Syracuse Crunch rally past Laval Rocket, 3-1

April 5, 2024 | seekingalpha.com

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

April 4, 2024 | wnewsj.com

Rocket offense explodes late in 21-11 win over Astros

April 2, 2024 | msn.com

Can the Rocket Hold Their Position? | Laval Week In Review

April 2, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Rocket Pharmaceuticals (RCKT)

April 2, 2024 | msn.com

Rocket Pharma gains as EU accepts gene therapy for review

April 2, 2024 | businesswire.com

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

April 1, 2024 | msn.com

Former Rocket reportedly taking low salary to play overseas

April 1, 2024 | msn.com

2024 NCAA Women’s Final Four court revealed at Rocket Mortgage Fieldhouse

March 31, 2024 | msn.com

Mavericks vs. Rocket Preview: 3 things to watch as Dallas takes on Houston

March 29, 2024 | msn.com

Skyler Miser helps bring Ringling Bros. back to DCU Center with a bang as the Human Rocket

March 27, 2024 | investing.com

Rocket Pharmaceuticals director sells over $7.79 million in company stock

March 26, 2024 | businesswire.com

Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team

See More Headlines

Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/26/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RCKT
CUSIP: N/A
CIK: 1281895
Web: www.rocketpharma.com
Phone: (609) 659-8001
Fax: 646-224-9585
Employees: 268
Year Founded: 2018

Price Target and Rating

Average Stock Price Target: $52.13
High Stock Price Target: $65.00
Low Stock Price Target: $39.00
Potential Upside/Downside: +114.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.89
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.94)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-245,600,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -51.83%
Return on Assets: -45.87%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 7.80
Quick Ratio: 7.80

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.46 per share
Price / Book: 4.45

Miscellaneous

Outstanding Shares: 90,500,000
Free Float: 62,357,000
Market Cap: $2.20 billion
Optionable: Optionable
Beta: 1.07

Social Links

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Gaurav D. Shah M.D. (Age 49)
CEO & Director
Comp: $1.05M
Mr. Mayo Pujols (Age 55)
Chief Technical Officer & Executive VP
Comp: $649.71k
Mr. Raj Prabhakar M.B.A. (Age 50)
Senior VP & Chief Business Officer
Comp: $619.13k
Kevin Giordano
Director of Corporate Communications
Ms. Isabel Carmona J.D.
Senior VP & Chief Human Resources Officer
Dr. Gayatri R. Rao J.D.
M.D., Chief Development Officer of LVV & Senior VP
Mr. Carlos Martin
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RCKT Stock Analysis - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RCKT shares.
View RCKT analyst ratings or view top-rated stocks.
What is Rocket Pharmaceuticals' stock price target for 2024?: 9 brokerages have issued 12-month target prices for Rocket Pharmaceuticals' shares. Their RCKT share price targets range from $39.00 to $65.00. On average, they predict the company's share price to reach $52.13 in the next twelve months. This suggests a possible upside of 120.1% from the stock's current price.
View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts.
How have RCKT shares performed in 2024?: Rocket Pharmaceuticals' stock was trading at $29.97 at the beginning of 2024. Since then, RCKT shares have decreased by 21.0% and is now trading at $23.68.
View the best growth stocks for 2024 here.
When is Rocket Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our RCKT earnings forecast.
How were Rocket Pharmaceuticals' earnings last quarter?: Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its quarterly earnings results on Monday, February, 26th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.14. During the same period in the previous year, the business posted ($0.92) EPS.

What ETFs hold Rocket Pharmaceuticals' stock?: ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Harbor Health Care ETF (MEDI), Harbor Disruptive Innovation ETF (INNO), Putnam BioRevolution ETF (SYNB) and SPDR S&P Biotech ETF (XBI).Franklin Genomic Advancements ETF (HELX).
What other stocks do shareholders of Rocket Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).
Who are Rocket Pharmaceuticals' major shareholders?: Rocket Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.26%) and Harbour Capital Advisors LLC (0.02%). Insiders that own company stock include David P Southwell, Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel, Mark Andrew White, Martin Wilson and Rtw Investments, Lp.
View institutional ownership trends.
How do I buy shares of Rocket Pharmaceuticals?: Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RCKT) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial